Contrast-Enhanced CT Texture Analysis in Colon Cancer: Correlation with Genetic Markers

Tomography. 2022 Aug 31;8(5):2193-2201. doi: 10.3390/tomography8050184.

Abstract

Background: The purpose of the study was to determine whether contrast-enhanced CT texture features relate to, and can predict, the presence of specific genetic mutations involved in CRC carcinogenesis. Materials and methods: This retrospective study analyzed the pre-operative CT in the venous phase of patients with CRC, who underwent testing for mutations in the KRAS, NRAS, BRAF, and MSI genes. Using a specific software based on CT images of each patient, for each slice including the tumor a region of interest was manually drawn along the margin, obtaining the volume of interest. A total of 56 texture parameters were extracted that were compared between the wild-type gene group and the mutated gene group. A p-value of <0.05 was considered statistically significant. Results: The study included 47 patients with stage III-IV CRC. Statistically significant differences between the MSS group and the MSI group were found in four parameters: GLRLM RLNU (area under the curve (AUC) 0.72, sensitivity (SE) 77.8%, specificity (SP) 65.8%), GLZLM SZHGE (AUC 0.79, SE 88.9%, SP 65.8%), GLZLM GLNU (AUC 0.74, SE 88.9%, SP 60.5%), and GLZLM ZLNU (AUC 0.77, SE 88.9%, SP 65.8%). Conclusions: The findings support the potential role of the CT texture analysis in detecting MSI in CRC based on pre-treatment CT scans.

Keywords: BRAF; KRAS; NRAS; colorectal cancer; computed tomography; genetic markers; microsatellite instability; mismatch repair; texture analysis.

MeSH terms

  • Colonic Neoplasms* / diagnostic imaging
  • Colonic Neoplasms* / genetics
  • Colonic Neoplasms* / pathology
  • Colorectal Neoplasms* / diagnosis
  • Colorectal Neoplasms* / genetics
  • Colorectal Neoplasms* / pathology
  • Genetic Markers
  • Humans
  • Proto-Oncogene Proteins B-raf / genetics
  • Proto-Oncogene Proteins p21(ras) / genetics
  • Retrospective Studies
  • Tomography, X-Ray Computed / methods

Substances

  • Genetic Markers
  • Proto-Oncogene Proteins B-raf
  • Proto-Oncogene Proteins p21(ras)

Grants and funding

This research received no external funding.